Imaging methods for visualizing implanted living cells

• US 20090209831A1
• Filed: 01/15/2009
• Published: 08/20/2009
• Est. Priority Date: 06/28/2000
• Status: Abandoned Application

• Current Assignee: Nexgen Medical Systems, Inc.
• Original Assignee: Nexgen Medical Systems, Inc.
• Inventors: Kucharczyk, John, Litman, Mark A.
• Application Number:
  US12/321,139
• Publication Number:
  US 20090209831A1
• Time in Patent Office: Days
• US Class Current: 600/301
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/413 Monitoring transplanted tissue or organ, e.g. for possible rejection reactions after a transplant

Abstract

A method is provided herein for indicating viability of cells grown on a rejection inert tissue cytoarchitecture or scaffolding with a medical device that supports at least one sensing function comprising:

• • non-destructively observing a region of a patient to where cells have been transplanted;
  • guiding the medical device to said region of a patient using the non-destructive observation;
  • positioning said medical device within said region of a patient using the non-destructive observation to assist in the positioning;
  • sensing a property within said region of a patient that is indicative of cell viability or nonviability; and
  • using data from sensing said property within said region to indicate cell viability from a transplant with the region. Magnetic Resonance Imaging is a particularly useful format for non-destructive observation of the region.

Claims

1. A method for indicating viability of transplanted progenitor or stem cells in an organ engineering environment, the method being performed with a medical device that supports at least one sensing function, the method comprising:

non-destructively observing a region of the growing tissue or organ where cells have been placed;

sensing a property within said region of the organ that is indicative of cell viability or nonviability of the cells; and

using data from sensing said property within said region to indicate cell viability from the cells on tissue cytoarchitecture within the organ wherein said cell viability is indicated by a property in cell chemistry resulting from an event selected from the group consisting of cell activity, cell inactivity, cell growth, cell death, specific cell function, specific cell dysfunction, volumetric expansion of cell population, and volumetric decrease of cell population.

15. The method of claim 1 wherein multiple tissues or organs from a single donor are simultaneously grown, cell viability or cell nonviability of the multiple tissues or organs is compared among each other, and a best organ is selected from among the multiple organs for implantation.

18. The method of claim 1 wherein the sensing of a property within said region of a patient that is indicative of cell viability or nonviability of the provided colony of cells is used to quantitate the cell viability.

20. The method of claim 15 wherein the sensing of a property within said region of the organ that is indicative of cell viability or nonviability of the provided cells is used to quantitate the cell viability.

2. A method for indicating viability of transplanted progenitor or stem cells in an organ engineering environment, the method being performed with a medical device that supports at least one sensing function, the method comprising:

non-destructively observing a region of the organ where cells have been positioned;

sensing a property within said region of the organ that is indicative of cell viability or nonviability of provided cells grown on tissue cytoarchitecture; and

using data from sensing said property within said region to indicate cell viability from the provided cells grown on the tissue cytoarchitecture within the region, wherein said non-destructively observing comprises magnetic resonance imaging and wherein said cell viability is indicated by a property in cell chemistry resulting from an event selected from the group consisting of cell activity, cell inactivity, cell growth, cell death, specific cell function, specific cell dysfunction, volumetric expansion of cell population, and volumetric decrease of cell population.

3. The method of claim 2 wherein sensing a property within said region of a patient that is indicative of cell viability or nonviability of transplanted progenitor or stem cells grown in a culture;

and

using data from sensing said property within said region to indicate cell viability from a transplant of progenitor or stem cells grown in a culture within the region wherein said property is monitored by observation of at least one parameter selected from the group consisting of local lactate levels, local glucose turnover, local phosphorous high-energy metabolite concentrations, local F-19 labeled metabolites, alterations in tissue sodium, and changes in the conversion rates of O₂ gas to H₂O water.

4. The method of claim 2 wherein said property is monitored by observation of at least one parameter selected from the group consisting of local lactate levels, local glucose turnover, local phosphorous high-energy metabolite concentrations, local F-19 labeled metabolites, alterations in tissue sodium, and changes in the conversion rates of O₂ gas to H₂O water.

5. The method of claim 2 wherein said property is monitored by at least one technique selected from the group consisting of proton spectroscopy, monitoring of C-13 labeled glucose, monitoring by P-31 MR spectroscopy, monitoring of local F-19 labeled metabolites, monitoring of Na-23 levels, and monitoring of 17O₂ gas conversion to H₂17O water.

6. The method of claim 2 wherein said property is monitored by at least one technique selected from the group consisting of proton spectroscopy, monitoring of C-13 labeled glucose, monitoring by P-31 MR spectroscopy, monitoring of local F-19 labeled metabolites, monitoring of Na-23 levels, and monitoring of 17O₂ gas conversion to H₂17O water.

7. The method of claim 2 wherein said medical device includes at least one element selected from the group consisting of a volume coil surrounding the tissue and a local multi-tuned MRI RF coil.

8. The method of claim 2 wherein said medical device includes at least one element selected from the group consisting of a volume coil surrounding the tissue and a local multi-tuned MRI RF coil.

16. The method of claim 2 wherein multiple tissues or organs from a single donor are simultaneously grown, cell viability or cell nonviability of the multiple tissues or organs is compared among each other, and a best organ is selected from among the multiple organs for implantation.

17. The method of claim 2 wherein there is sensing a property within said region of a patient that is indicative of cell metabolism;

then repeating or continuing said sensing of a property over a period of time in which said property changes; and

using data from sensing changes in said property within said region to indicate cell viability in the organ cells,

wherein said data from sensing changes in said property indicates active metabolic function in provided cells, and wherein changes in said property are monitored by at least one technique selected from the group consisting of proton spectroscopy, monitoring of C-13 labeled glucose, monitoring by P-31 MR spectroscopy, monitoring of local F-19 labeled metabolites, monitoring of Na-23 levels, and monitoring of 17O₂ gas conversion to H₂ 17O water.

19. The method of claim 2 wherein the sensing of a property within said region of a patient that is indicative of cell viability or nonviability of the provided cells is used to quantitate the cell viability.

10. A method for indicating viability of cells grown as complete transplantable organ during growth of the organ or after growth of the complete organ by cell growth over a cell rejection inert scaffolding, the method being performed with a medical device that supports at least one sensing function, the method comprising:

non-destructively observing a region of the organ where cells have been provided on the scaffolding and cells are growing;

sensing a property within said region of the organ that is indicative of cell viability or nonviability of provided cells; and

using data from sensing said property within said region to indicate cell viability within the organ wherein said property comprises blood flow or changes in blood flow as vascular supply is developed.

9. The method of claim 12 wherein said medical device includes at least one element selected from the group consisting of a volume coil surrounding the tissue and a local multi-tuned MRI RF coil.

11. The method of claim 10 wherein said non-destructively observing comprises magnetic resonance imaging and said property comprises blood flow or changes in blood flow as vascular supply is developed.

12. The method of claim 10 wherein said property is monitored by observation of at least one parameter selected from the group consisting of local lactate levels, local glucose turnover, local phosphorous high-energy metabolite concentrations, local F-19 labeled metabolites, alterations in tissue sodium, and changes in the conversion rates of O₂ gas to H₂O water said property comprises blood flow or changes in blood flow as vascular supply is developed.

13. The method of claim 10 wherein blood flow or changes in blood flow are measured by observation of at least one material selected from the group consisting of labeled H₂O water, contrast-agent infusion of TI-shortening agents or T2*-shortening agents, local introduction of hyperpolarized Xenon gas, or optically-active coloring agents.

14. The method of claim 11 wherein blood flow or changes in blood flow are measured by observation of at least one material selected from the group consisting of labeled H₂O water, contrast-agent infusion of TI-shortening agents or T2*-shortening agents, local introduction of hyperpolarized Xenon gas, or optically-active coloring agents.